Free Trial
NASDAQ:CHGA

Avalon GloboCare Q3 2024 Earnings Results & Report

Avalon GloboCare logo
$2.02 +0.01 (+0.50%)
As of 10/9/2026 04:00 PM Eastern

Avalon GloboCare reported Q3 2024 earnings on November 12, 2024. The company reported EPS of -$36.40, while revenue was $0.35 million.

Earnings Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call
7:00 AM ET

Avalon GloboCare EPS Results

Actual EPS
-$36.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
$0.35 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Avalon GloboCare Q3 2024 Earnings FAQ

Avalon GloboCare (NASDAQ:CHGA) reported earnings of -$36.40 per share for Q3 2024. The report was announced on Tuesday, November 12, 2024.

Avalon GloboCare reported revenue of $0.35 million for Q3 2024.

Avalon GloboCare Earnings Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:CHGA) is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey. Publicly available company materials have identified David Jin as a senior executive, although the company’s operating status, leadership and securities information may have changed. Avalon GloboCare has historically traded under the symbol AVCO; the symbol provided, CHGA, could not be independently confirmed as its current listing.

View Avalon GloboCare Profile